MiNK Therapeutics (INKT) Notes Payables (2021)
MiNK Therapeutics (INKT) posted Notes Payables of $65.4 million for Q3 2021.
MiNK Therapeutics (INKT) Notes Payables (2021) Analysis & Trends
MiNK Therapeutics has reported Notes Payables for 1 years, with the latest figure at $65.4 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - |
| 10 | MiNK Therapeutics | 61.20 Mn | 61.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 65.42 Mn |